Recursion Pharmaceuticals' Chief R&D Commercial Officer, Najat Khan, was granted 496,972 shares of Class A Common Stock on August 1, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following the transaction, Khan directly holds a total of 496,972 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.

Recursion Pharmaceuticals' Chief R&D Commercial Officer, Najat Khan, was granted 496,972 shares of Class A Common Stock on August 1, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following the transaction, Khan directly holds a total of 496,972 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.